Literature DB >> 19071316

Determination of clarithromycin in rat plasma by HPLC-UV method with pre-column derivatization.

Wei Li1, Huijuan Jia, Kang Zhao.   

Abstract

A novel high-performance liquid chromatographic (HPLC) method using pre-column derivatization and UV detection at 275nm for the determination of clarithromycin in rat plasma has been validated. Clarithromycin was extracted from plasma sample spiked with internal standard (erythromycin) under alkaline condition with ethyl ether and derivatizated with trimethylbromosilane. The analyses were run on a C(18) column, maintained at 40 degrees C during elution, using a mobile phase comprised of potassium dihydrogen phosphate (50mM, pH 6.8, contained 0.7% triethylamine), acetonitrile, and methanol (30:45:25, v/v/v). The standard calibration curve for clarithromycin was linear (r(2)=0.9998) over the concentration range of 0.1-10mugml(-1) in rat plasma. The limit of detection (LOD) and limit of quantitation (LOQ) was 30ngml(-1) and 0.1mugml(-1) respectively. The intra- and inter-day assay variability range was 2.6-7.4% and 3.3-8.5%, respectively. This method has been successfully applied to a pharmacokinetic study of clarithromycin in rats.

Entities:  

Year:  2006        PMID: 19071316     DOI: 10.1016/j.talanta.2006.04.015

Source DB:  PubMed          Journal:  Talanta        ISSN: 0039-9140            Impact factor:   6.057


  2 in total

1.  Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication.

Authors:  Kai Y Liu; Fang C Du; Qiang Fu; Wei J Zhang; Hong W Sun; Yi Zhang; Le L Gan; Zhi Y Yue; Quan M Zou; Gang Guo
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Rapid high performance liquid chromatographic method for determination of clarithromycin in human plasma using amperometric detection: application in pharmacokinetic and bioequivalence studies.

Authors:  Seyed Mohsen Foroutan; Afshin Zarghi; Alireza Shafaati; Babak Madadian; Farshid Abolfathi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.